Today: 21 May 2026
Meta stock edges higher after nuclear power deals aimed at AI data centers

Meta stock edges higher after nuclear power deals aimed at AI data centers

NEW YORK, January 9, 2026, 16:30 EST — After-hours

  • Meta shares were up about 1% in late trading after it outlined nuclear power agreements linked to its AI buildout
  • The company said the deals could back as much as 6.6 gigawatts of nuclear capacity by 2035
  • Investors are now keeping an eye on project timelines, permitting and Meta’s next earnings update

Meta Platforms, Inc. shares rose 1.1% to $653.06 in after-hours trading on Friday after the Facebook owner unveiled a slate of nuclear power agreements meant to supply its power-hungry AI data centers. Meta said deals with Vistra, Oklo and TerraPower could back as much as 6.6 gigawatts of new and existing nuclear capacity by 2035.

The effort comes as power supply is becoming a choke point for data center growth, particularly in areas where generation is already scarce. It also follows Meta’s December request for proposals for new nuclear development and extends its earlier nuclear deal with Constellation Energy, with the power aimed at PJM — the regional grid operator covering much of the Mid-Atlantic and Midwest.

Meta linked the plan to Prometheus, an AI data center project in New Albany, Ohio, that it has described as a 1-gigawatt cluster spanning multiple buildings and slated to come online in 2026. Financial terms of the deals were not disclosed.

Vistra said it has signed 20-year power purchase agreements — long-term contracts to buy electricity — covering more than 2,600 megawatts of nuclear power supply, including 433 MW from output boosts known as uprates. “This is a unique and exciting collaboration,” Vistra CEO Jim Burke said. Meta’s head of global energy Urvi Parekh said Meta is putting money behind the deal because nuclear delivers “clean, reliable power” for its AI ambitions. PR Newswire

Vistra said in a filing that deliveries under the agreements start in late 2026 and ramp to full operating output by the end of 2027, while uprate capacity is slated to come online in phases through 2034. The company also expects capital spending to begin in 2026 to support the uprates, with less than 20% of the total outlay projected by the end of 2028.

Oklo said the Meta agreement lays out a structure for Meta to prepay for power and help bankroll early work on a 1.2-gigawatt campus spanning 206 acres in Pike County, Ohio. Site work is expected to start in 2026, with first power targeted as early as 2030. “Two years ago, Oklo shared its vision to build a new generation of advanced reactors in Ohio. Today, that vision is becoming a reality,” co-founder and CEO Jacob DeWitte said. Oklo

TerraPower said it has an agreement with Meta to develop as many as eight Natrium reactors, delivering up to 2.8 GW of carbon-free baseload — steady, around-the-clock — power and as much as 4 GW when combined with built-in storage. “To successfully address growing energy demand, we must deploy gigawatts of advanced nuclear energy in the 2030s,” TerraPower CEO Chris Levesque said. PR Newswire

Oklo shares were up about 8% in late trading. Vistra gained about 10%, and Constellation Energy rose about 6%. The takeaway was straightforward: AI infrastructure needs power contracts that run for decades, and nuclear is back in the conversation.

Meta’s near-term payoff is hard to pin down, with most of the new-build components still years away and exposed to regulatory hurdles and execution risk. Small modular reactors — smaller nuclear units designed for factory builds — still aren’t operating commercially in the United States and the projects will need permits, Reuters reported; backers say the designs can lower costs, while critics doubt they’ll ever scale the way large reactors do.

Meta investors are looking to the company’s next earnings update for signals on 2026 capital spending and the pace at which its AI push is driving power demand. Zacks expects Meta to report quarterly results on February 4.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Eaton stock rises today as Barclays trims target; CPI and earnings loom
Previous Story

Eaton stock rises today as Barclays trims target; CPI and earnings loom

Applied Digital stock jumps again as AI data-center demand and hyperscaler talks drive the tape
Next Story

Applied Digital stock jumps again as AI data-center demand and hyperscaler talks drive the tape

Go toTop